- FDA approves atezolizumab for PD|L1 positive unresectable locally ...🔍
- FDA Approves Atezolizumab for PD|L1 Positive Unresectable Locally🔍
- FDA Approval Summary🔍
- Update on U.S. Indication for Atezolizumab in PD|L1–Positive ...🔍
- FDA Approves Tecentriq plus Abraxane—First Immunotherapy for ...🔍
- FDA approves Tecentriq combination for PD|L1|positive🔍
- Atezolizumab for use in PD|L1|positive unresectable🔍
- Press Releases🔍
FDA approves atezolizumab for PD|L1 positive unresectable locally ...
FDA approves atezolizumab for PD-L1 positive unresectable locally ...
On March 8, 2019, the Food and Drug Administration granted accelerated approval to atezolizumab (TECENTRIQ, Genentech Inc.) in combination ...
FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally
FDA Approves Atezolizumab for PD-L1 Positive Unresectable Locally Advanced or Metastatic TNBC ... On 8 March 2019, the US Food and Drug ...
FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein ...
... unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 [PD-L1 stained tumor-infiltrating i
Update on U.S. Indication for Atezolizumab in PD-L1–Positive ...
... unresectable locally advanced or metastatic triple-negative breast ... Atezolizumab was granted accelerated approval by the FDA for the ...
FDA Approves Tecentriq plus Abraxane—First Immunotherapy for ...
... PD-L1–positive unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) ... This is the fifth approval for the PD-L1 inhibitor ...
FDA approves Tecentriq combination for PD-L1-positive, triple ...
The FDA granted accelerated approval to atezolizumab plus chemotherapy for the treatment of adults with PD-L1-positive, unresectable, locally ...
Atezolizumab for use in PD-L1-positive unresectable, locally ...
Since the US FDA-approval of the first immune checkpoint inhibitor, anticytotoxic T-lymphocyte antigen-4 monoclonal antibody ipilimumab, for metastatic ...
The company has made the decision to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, ...
FDA approves atezolizumab and hyaluronidase-tqjs
A total of 371 patients were randomized (2:1) to receive subcutaneous atezolizumab and hyaluronidase-tqjs or intravenous atezolizumab until ...
Atezolizumab TNBC Indication Withdrawn By Manufacturer After ...
FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. FDA. March 8, 2019 ...
FDA Approves Atezolizumab Combo for Frontline TNBC - OncLive
... unresectable locally advanced or metastatic PD-L1—positive triple-negative breast cancer (TNBC). The approval is based on the phase III ...
First Immunotherapeutic Approved for Breast Cancer | The AACR
Among patients who had unresectable locally advanced or metastatic triple-negative breast cancer that tested positive for PD-L1, adding atezolizumab to nab- ...
Atezolizumab - SEER*Rx Interactive Antineoplastic Drugs Database
March 8, 2019 FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. 12/6/2018 FDA approved ...
FDA issues alert about efficacy and potential safety concerns with ...
Continued approval of atezolizumab in combination with ... atezolizumab in both the PD-L1-positive population and total population.
Still the Standard of Care for Metastatic Triple-Negative Breast Cancer
... approval of atezolizumab and nab-paclitaxel for PD-L1–positive mTNBC. ... atezolizumab for unresectable locally advanced/metastatic triple ...
Roche Withdraws Atezolizumab PD-L1–Positive Metastatic TNBC ...
FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer. News release. FDA.
FDA Advisory Committee Votes in Favor of Maintaining Accelerated Approval of Genentech's Tecentriq for PD-L1-Positive, Metastatic Triple-Negative Breast Cancer.
FDA approves atezolizumab for BRAF V600 unresectable or ...
in combination with cobimetinib and vemurafenib for patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. Efficacy ...
Atezolizumab and Its Many Uses - Cancer Network
U.S. Food and Drug Administration. FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative ...
FDA ODAC Votes in Favor of Maintaining Accelerated Approval of ...
The combination treatment was granted accelerated approval in March 2019 for the treatment of adults with PD-L1–positive, unresectable locally ...